Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
It is well-tolerated, extensively studied, and provides a strong foundation before adding more targeted peptides
Gupta, R
A few things make GHK-Cu unusual among peptide therapies: In plain language: GHK-Cu is one of your body's natural "repair signals," and replenishing it may help restore the regenerative signaling that quietly weakens over time
Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. The Journal of nutrition vol
Puglisi R, Tramer F, Panfili E, Micali F, Sandri G, Boitani C